Screener
Climb Bio, Inc. CLYM EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
FAQ
- What is Climb Bio, Inc.'s EPS (diluted)?
- Climb Bio, Inc. (CLYM) reported EPS (diluted) of -$0.20 in Q1 2026.
- How has Climb Bio, Inc.'s EPS (diluted) changed year-over-year?
- Climb Bio, Inc.'s EPS (diluted) increased by 35.5% year-over-year, from -$0.31 to -$0.20.
- What is the long-term trend for Climb Bio, Inc.'s EPS (diluted)?
- Over 2 years (2022 to 2025), Climb Bio, Inc.'s EPS (diluted) has grown at a -24.2% compound annual growth rate (CAGR), from -$1.53 to -$0.88.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Climb Bio, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude